Bonefos and the Consumption of Analgesics

Bayer149 enrolled

Overview

The effect of Bonefos on consumption of analgesics (drugs used for pain treatment) in patients with proven bone metastases.

Study Type

OBSERVATIONAL

Enrollment

149

Conditions

Bone Neoplasms

Interventions

Bonefos (Clodronate, BAY94-8393)DRUG

Patients in regular clinical practice receiving Bonefos according to local drug information

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Breast cancer or prostate cancer or multiple myeloma. * Bone metastasis. * Ability to use analgesics and clodronate 1600 mg/day. Exclusion Criteria: * Hypersensitivity to bisphosphonates. * Clodronate in previous therapy. * Concomitant use of other bisphosphonates. * Serious renal insufficiency.

Locations (1)

Unnamed facility

Many Locations, Czechia

Outcomes

Primary Outcomes

Analgesics consumption after 12 months of treatment with Bonefos in patients with bone metastases and breast or prostate cancer or multiple myeloma

Time frame: 12 months

Secondary Outcomes

Decrease in pain measured by VAS (Visual Analogue Scale)

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.